Group 1 - The company has completed the construction of the lithium sulfide pilot line as planned and is currently advancing the trial production work in an orderly manner [2]

Core Viewpoint - Haicheng Pharmaceutical has received approval from the National Medical Products Administration for the registration of Aximol capsules, which are indicated for patients with high triglyceride levels who do not respond adequately to other treatments [1] Group 1: Product Approval - The product Aximol is approved for use as a replacement or adjunct therapy to lower triglyceride levels in patients [1] - It is specifically indicated for Fredrickson Type IV hyperlipoproteinemia and Fredrickson Type IIb hyperlipoproteinemia [1] - The medication is to be used after dietary changes and other non-drug treatments, such as exercise and weight loss, have been attempted [1]

Group 1 - The core point of the article is that Haichen Pharmaceutical has received approval from the National Medical Products Administration for its product "Aximol" capsules [1] - Haichen Pharmaceutical's revenue composition for the year 2024 is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [2] - As of the latest report, Haichen Pharmaceutical has a market capitalization of 6.4 billion yuan [3] Group 2 - The article highlights that Chinese innovative drugs have generated $80 billion in overseas licensing this year, indicating a robust market for biopharmaceuticals [3] - There is a contrast noted between the hot secondary market for biopharmaceuticals and the cooling fundraising environment in the primary market [3]

证券代码：300584 证券简称：海辰药业 公告编号：2025-051 南京海辰药业股份有限公司 关于公司阿昔莫司胶囊获得药品注册批件的公告 剂型：胶囊剂 规格：0.25g 注册分类：化学药品 4 类 上市许可持有人：南京海辰药业股份有限公司 上市许可持有人地址：南京经济技术开发区恒发路 1 号 生产企业：南京海辰药业股份有限公司 生产企业地址：南京经济技术开发区恒发路 1 号 证书编号：2025S03220 药品批准文号：国药准字 H20255770 酯血症（FredricksonIV 型高脂蛋白血症）、高胆固醇和高甘油三酯血症 （FredricksonIIb 型高脂蛋白血症），在采取饮食改变和其他非药物治疗（如运 动、减肥）等其他措施之后方可使用该药品。 阿昔莫司胶囊由辉瑞研制，最早于 1988 年 3 月获瑞士批准上市，1994 年 6 月，经国家药品监督管理局批准，阿昔莫司胶囊在国内上市。经查询国家药监 局网站，除公司外，目前有石家庄四药有限公司、鲁南贝特制药有限公司、四 川豪运药业股份有限公司、浙江赛默制药有限公司、北京福元医药股份有限公 司、地奥集团成都药业股份有限公司获批。 三、对公司的影响 南 ...

Group 1 - Sanwang Communication plans to repurchase shares worth 20-40 million yuan for employee stock incentive plans [1] - Ankrui reported a net profit of 192 million yuan for the first three quarters, a year-on-year increase of 21.31% [1] - Taishan Petroleum's net profit for the first three quarters reached 113 million yuan, up 112.32% year-on-year [1] - Zhejiang Xiantong achieved a net profit of 152 million yuan for the first three quarters, a 17.4% increase year-on-year [1] Group 2 - Xuanji Information reported a net loss of 173 million yuan for the first three quarters [1] - Mailande's net profit slightly decreased by 0.07% to 96 million yuan for the first three quarters [1] - Tengjing Technology's subsidiary received a sales order worth 87.61 million yuan [1] Group 3 - Hotgen Biotech's affiliate achieved positive results in Phase Ib clinical trials for the innovative drug SGC001 [1] - Zhongyan Dadi won a bid for a sports project in Beijing worth 74.04 million yuan [1] - Henghui Security's net profit decreased by 12.85% to 81.98 million yuan for the first three quarters [1] Group 4 - Xiongdi Technology's net profit increased by 71.16% to 18.38 million yuan for the first three quarters [1] - Meilixin reported a net loss of 215 million yuan for the first three quarters [1] - Haichen Pharmaceutical's net profit grew by 16.22% to 32.68 million yuan for the first three quarters [1] Group 5 - Qiaoyuan Co. reported a net profit of 181 million yuan for the first three quarters, a 40.54% increase year-on-year [1] - Fuda Co. achieved a net profit of 221 million yuan for the first three quarters, up 83.27% year-on-year [1] - Xianggang Technology's net profit surged by 186.19% to 95.47 million yuan for the first three quarters [1] Group 6 - ST Nanchuan received a restriction order from the court due to a financial dispute [1] - Changyou Technology announced the dismissal of two vice presidents [1] - Haoyuan Automotive received a project confirmation for an automatic parking system worth 576 million yuan [1] Group 7 - Jiuzhou Biotech obtained a medical device registration certificate for a diagnostic kit [1] - Shihua Machinery signed an investment intention letter for a subsidiary's capital increase [1] - Zhuhai Mian Group plans to transfer 100% equity of Gree Real Estate [1] Group 8 - Dalian Heavy Industry reported a net profit of 490 million yuan for the first three quarters, a 23.97% increase year-on-year [1] - Haimeng Data reported a net loss of 75.43 million yuan for the first three quarters [1] - Feilong Co. achieved a net profit of 287 million yuan for the first three quarters, a 7.54% increase year-on-year [1] Group 9 - Kaipu Testing reported a net profit of 57.84 million yuan for the first three quarters, a 3.34% increase year-on-year [1] - Ganyue Express signed a strategic cooperation agreement with a major energy company [1] - Tuoshan Heavy Industry's controlling shareholder plans to reduce its stake by 2.82% [1] Group 10 - Yiatong's shareholder plans to reduce its stake by 1% [1] - Weishi Electronics reported a net profit of 24.29 million yuan for the first three quarters, a 22.59% decrease year-on-year [1] - Shensi Electronics won a bid for a data space construction project worth 161 million yuan [1] Group 11 - Xiechuang Data plans to purchase server assets worth up to 4 billion yuan [1] - Shandong Express's controlling shareholder plans to transfer 7% of its shares [1] - ST Huapeng's subsidiary received a government subsidy of 4.65 million yuan [1] Group 12 - Jieqiang Equipment's shareholder plans to reduce its stake by 1% [1] - China Jushi reported a net profit of 2.568 billion yuan for the first three quarters, a 67.51% increase year-on-year [1] - ST Fanli reported a net loss of 44.78 million yuan for the first three quarters [1] Group 13 - Xiyu Tourism reported a net profit of 98.58 million yuan for the first three quarters, a 14.51% decrease year-on-year [1] - Abison reported a net profit of 185 million yuan for the first three quarters, a 57.33% increase year-on-year [1] - Huayan Precision reported a net profit of 70.76 million yuan for the first three quarters, a 31.07% increase year-on-year [1] Group 14 - Jiangling Motors reported a net profit of 74.9 million yuan for the first three quarters, a 35.76% decrease year-on-year [1]

智通财经APP讯，海辰药业(300584.SZ)发布2025年三季度报告，前三季度，公司实现营业收入4.72亿 元，同比增长30.80%。归属于上市公司股东的净利润3267.85万元，同比增长16.22%。归属于上市公司 股东的扣除非经常性损益的净利润2954.31万元，同比增长1.64%。 ...

格隆汇10月22日丨海辰药业(300584.SZ)公布三季度报告，前三季营业收入4.7亿元，同比增长30.80%， 归属于上市公司股东的净利润3267.85万元，同比增长16.22%，归属于上市公司股东的扣除非经常性损 益的净利润2954万元，同比增长1.64%。 ...

Company Overview - Haichen Pharmaceutical (SZ 300584) announced on October 22 that its fifth board meeting was held via telecommunication to review the full report for the third quarter of 2025 [1] - The company's revenue composition for the period from January to December 2024 is entirely from the pharmaceutical manufacturing sector, accounting for 100.0% [1] - As of the report, Haichen Pharmaceutical has a market capitalization of 6.7 billion yuan [1]

证券代码：300584 证券简称：海辰药业 公告编号：2025-049 南京海辰药业股份有限公司 第五届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长曹于平先生召集，会议通知于 2025 年 10 月 17 日电 话、电子邮件、专人送达等形式送达至各位董事，董事会会议通知中包括会议的 相关材料，同时列明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2025 年 10 月 22 日以通讯表决方式召开。 3、本次董事会应出席 7 人，实际出席会议人数为 7 人。 会议审议并通过如下议案： 1、审议通过《2025 年第三季度报告全文》 经审核，董事会认为编制和审核南京海辰药业股份有限公司 2025 年第三季 度报告的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、 完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 公司董事会批准报出公司《2025 年第三季度报告全文》。具体内容详见公司同 日披露在中国证监会创业板指定信息披露网站巨潮资讯网的相关公 ...

Revenue and Profit - The company's revenue for Q3 2025 reached ¥162,954,321.51, representing a year-on-year increase of 31.45%[5] - Net profit attributable to shareholders was ¥3,520,760.91, up 4.15% compared to the same period last year[5] - Operating revenue increased by 30.80% to ¥471,526,892.93 compared to ¥360,497,824.16 in the same period last year, primarily due to growth in the injection of hydrochloride lanadelumab business[9] - Total operating revenue for the current period reached ¥471,526,892.93, an increase from ¥360,497,824.16 in the previous period, representing a growth of approximately 30.9%[17] - Net profit for the current period was ¥32,194,633.14, compared to ¥28,116,806.63 in the previous period, reflecting an increase of approximately 14.8%[18] - Total comprehensive income for the period attributable to the parent company was CNY 32,678,503.32, compared to CNY 28,116,806.63 in the previous period, representing an increase of approximately 15.5%[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,483,375,637.55, an increase of 1.29% from the end of the previous year[5] - The company’s total assets increased to ¥1,483,375,637.55 from ¥1,464,546,955.74, marking a growth of about 1.3%[16] - The company’s total liabilities decreased to ¥410,137,814.43 from ¥426,373,270.65, a reduction of approximately 3.8%[16] - The total equity attributable to shareholders increased to ¥1,043,329,086.59 from ¥1,022,936,243.51, reflecting a growth of about 1.98%[16] Cash Flow - Cash flow from operating activities for the year-to-date reached ¥58,486,668.79, up 33.09%[5] - Net cash flow from operating activities increased by 33.09% to ¥58,486,668.79 from ¥43,945,167.75, attributed to higher cash inflows from product sales[9] - Cash inflow from operating activities totaled CNY 477,727,059.54, compared to CNY 398,528,192.31 in the previous period, marking an increase of about 19.9%[21] - Cash outflow from operating activities was CNY 419,240,390.75, up from CNY 354,583,024.56, which is an increase of approximately 18.2%[22] - The ending balance of cash and cash equivalents was CNY 76,144,155.15, compared to CNY 38,197,993.87 in the previous period, indicating a significant increase[22] Expenses - Management expenses rose by 64.56% to ¥104,692,101.85 from ¥63,620,585.66, mainly due to the inclusion of pre-research expenses for unapproved R&D projects[9] - Research and development expenses for the current period were ¥31,204,448.18, down from ¥34,268,297.38, a decrease of about 9.5%[18] Other Financial Metrics - The basic earnings per share for the period was ¥0.0293, reflecting a 3.90% increase year-on-year[5] - Basic and diluted earnings per share increased to CNY 0.2723 from CNY 0.2343, reflecting a growth of about 16.5%[19] - The company reported a significant increase of 469.63% in other receivables, totaling ¥466,728.92, attributed to increased receivables and reserves[8] - The company reported an investment loss of ¥2,763,924.66, primarily due to investments made by the subsidiary Anqing Huichen[9] - The total deferred tax liabilities decreased by 32.40% to ¥8,436,277.90 from ¥12,480,575.90, mainly due to the reduction in deferred tax expenses recognized at the end of the previous year[9] Financing Activities - The net cash flow from financing activities decreased by 414.57% to -¥21,988,756.49 from ¥6,990,069.18, reflecting a reduction in financing loan amounts compared to the previous year[9] - Cash inflow from financing activities was CNY 203,100,000.00, down from CNY 251,100,483.33, representing a decrease of about 18.9%[22] - The company raised CNY 15,000,000.00 from minority shareholders during the financing activities[22] Other Information - The company experienced a 91.90% decrease in employee compensation payable, amounting to ¥352,240.86, due to the distribution of annual bonuses[8] - The third quarter financial report was not audited, which may impact the reliability of the reported figures[23]